Synthroid vs Armour Thyroid: Head-to-Head Efficacy Compared

What Each Drug Contains and How It Works

Levothyroxine (brand name Synthroid) is a synthetic form of thyroxine (T4). After oral absorption, peripheral deiodinase enzymes in the liver, kidneys, and other tissues convert T4 into triiodothyronine (T3), the biologically active hormone that drives metabolic rate, cardiac output, and thermoregulation. This conversion pathway means the body regulates its own T3 supply from a stable T4 reservoir, which produces predictable serum levels and a long half-life of approximately 6 to 7 days 1.

Armour Thyroid is a desiccated porcine thyroid extract containing both T4 and T3 in a fixed ratio of roughly 4.2:1 by weight. The human thyroid secretes T4 and T3 at approximately a 14:1 ratio, so NDT delivers a proportionally higher T3 dose per milligram of T4 than the body would produce on its own 2. This exogenous T3 component is absorbed rapidly, producing a serum T3 spike within 2 to 4 hours of ingestion that gradually falls before the next dose. Patients sometimes split their daily NDT dose to reduce this peak-to-trough variation, although no guideline formally recommends this practice.

The pharmacokinetic difference is the core of the debate. Levothyroxine offers a flat, steady-state T3 profile through peripheral conversion. NDT delivers both hormones directly, which can raise free T3 above the reference range transiently while keeping TSH normal. Whether that T3 peak confers a clinical benefit or introduces a cardiac risk remains unresolved by current trial data.

The ATA Guidelines: Why Levothyroxine Is First-Line

The American Thyroid Association's 2014 clinical practice guidelines for the treatment of hypothyroidism recommend levothyroxine monotherapy as the standard of care 1. The panel rated this as a "strong recommendation" based on its long track record of efficacy, consistent potency across manufacturers (when using the same brand or FDA AB-rated generic), and well-characterized dose-response relationship.

The guideline authors acknowledged that some patients report residual symptoms on levothyroxine despite normalized TSH. They noted this is "an area requiring further research" but stopped short of recommending NDT or combination T4/T3 therapy as alternatives outside of clinical trials. Their reasoning centered on three concerns: the supraphysiologic T3 peaks that NDT produces, the lack of long-term safety data from randomized trials, and inconsistent potency across NDT lots, since NDT is not held to the same bioequivalence standards as synthetic levothyroxine.

Dr. Victor Bernet, then chair of the ATA's patient education committee, stated in the guideline's supplementary materials: "We are not saying desiccated thyroid cannot work for individual patients. We are saying the evidence base for levothyroxine is far deeper, and the pharmacokinetic profile is more predictable." This distinction matters. The ATA's position is not that NDT is harmful. It is that levothyroxine has more supporting evidence, and the guidelines reflect that asymmetry.

One limitation of the 2014 guidelines worth noting: the panel reviewed 13 randomized trials comparing T4 monotherapy to combination T4+T3 therapy, but most used synthetic liothyronine (Cytomel) rather than NDT. Only one of those trials used desiccated thyroid extract specifically 2. The evidence base the ATA relied on was strong for levothyroxine but thin for NDT in particular.

The Hoang Trial: The Best Direct Comparison Available

The most rigorous head-to-head data comes from a 2013 randomized, double-blind, crossover trial published in the Journal of Clinical Endocrinology & Metabolism by Hoang et al. 2. This study enrolled 70 hypothyroid patients already stable on levothyroxine and randomized them to either continue levothyroxine or switch to dose-equivalent NDT for 16 weeks, then cross over to the other treatment for another 16 weeks.

The primary outcomes were TSH, free T4, and free T3 at the end of each treatment period. Results showed no statistically significant difference in TSH between the two arms. Both drugs normalized TSH effectively. Free T4 was slightly lower on NDT (as expected, since NDT supplies less T4 per grain than a standard levothyroxine dose), while free T3 was slightly higher on NDT, also as expected given the exogenous T3 content.

Here is where the data becomes interesting. At study end, patients were asked which treatment they preferred. A striking 48.6% preferred NDT compared with 18.6% who preferred levothyroxine (P=0.002). The remaining patients had no preference. Patients on NDT also lost an average of 1.5 kg more than they did during the levothyroxine phase, a modest but statistically significant difference.

The Hoang trial did not find differences in cognitive function, quality of life scores (SF-36), or symptoms of depression (BDI-II) between the two treatments. The patient preference signal was clear, but the validated psychometric instruments did not capture what was driving it. The authors speculated that the weight loss, the higher T3 levels, or unmeasured subjective factors could explain the preference gap.

Two important caveats apply to this trial. The sample size of 70 is modest, limiting statistical power for secondary outcomes. And the 16-week crossover periods may have been too short to detect longer-term differences in bone density, cardiovascular events, or sustained weight change. No subsequent trial with a larger sample has replicated or extended these findings.

TSH Normalization: Both Drugs Perform Similarly

If the primary clinical goal is bringing TSH into the reference range (typically 0.4 to 4.0 mIU/L, or 0.5 to 2.5 mIU/L for tighter targets), both levothyroxine and NDT accomplish this reliably when dosed appropriately 1. The Hoang trial confirmed equivalent TSH outcomes in a controlled setting 2. Retrospective chart reviews from integrative medicine practices report similar TSH normalization rates, though these lack the controls of a randomized design.

The dosing math differs between the two. Standard levothyroxine dosing starts at 1.6 mcg/kg/day for full replacement in adults without cardiac disease 1. For Armour Thyroid, 1 grain (60 mg) contains approximately 38 mcg of T4 and 9 mcg of T3. Because T3 is roughly three to four times more metabolically potent than T4 on a microgram basis, 1 grain of Armour is often considered roughly equivalent to 88 to 100 mcg of levothyroxine, though conversion ratios vary among clinicians and no official equivalence table exists.

TSH monitoring intervals are the same for both drugs: recheck 6 to 8 weeks after any dose change, then every 6 to 12 months once stable. Patients on NDT may need more frequent monitoring early on because the T3 component can suppress TSH more aggressively than expected, particularly in older adults or those with cardiac risk factors.

Beyond TSH: The T3 Question

The most persistent criticism of levothyroxine monotherapy is that it relies entirely on peripheral conversion of T4 to T3. Some patients carry polymorphisms in the DIO2 gene (which encodes the type 2 deiodinase enzyme) that may impair this conversion. A 2009 study in the Journal of Clinical Endocrinology & Metabolism found that the Thr92Ala DIO2 polymorphism, present in roughly 16% of the population, was associated with worse psychological well-being on levothyroxine monotherapy 3.

This finding has not been consistently replicated. A 2016 systematic review of DIO2 polymorphism studies found mixed results, with some studies showing an association with patient preference for combination therapy and others showing no effect 4. The European Thyroid Association's 2012 guidelines acknowledged the theoretical basis for combination therapy in patients with DIO2 polymorphisms but called for larger trials before making clinical recommendations 5.

Free T3 levels in patients on levothyroxine monotherapy typically sit in the lower third of the reference range. On NDT, free T3 values often reach the mid-to-upper third or even transiently exceed the upper limit after dosing. Whether this higher T3 exposure translates to better symptom control for a subgroup of patients or increases atrial fibrillation risk in an older population is the central unanswered question.

A population-level answer does not exist yet. No trial has been powered to detect differences in atrial fibrillation, bone mineral density, or all-cause mortality between levothyroxine and NDT. The largest observational dataset, a 2021 retrospective cohort study from Mederi Health (published on the preprint server but not yet peer-reviewed in a major journal), suggested no increase in atrial fibrillation among NDT users, but the study's methodology drew criticism for inadequate adjustment of confounders.

Safety Profile Comparison

Both medications have established safety profiles when dosed to keep TSH within the target range. The primary risks of either drug are the same: overtreatment (suppressed TSH) increases the risk of atrial fibrillation and accelerated bone loss, while undertreatment leaves hypothyroid symptoms uncontrolled 1.

Levothyroxine's safety record spans decades and millions of patient-years. The FDA classifies it as a narrow therapeutic index drug, meaning small dose changes produce meaningful shifts in serum levels 6. This is why the ATA recommends patients stay on the same brand or generic manufacturer when possible, to avoid potency variability between formulations.

Armour Thyroid does not carry the same narrow therapeutic index classification because it is regulated differently. NDT products are marketed under the FDA's pre-1962 approval framework. They were never required to undergo the same bioequivalence testing as synthetic levothyroxine generics. Allergan (now AbbVie), the manufacturer of Armour Thyroid, conducts lot-to-lot testing, but the T4/T3 content can vary by up to 10% between batches per USP standards. Critics argue this variability makes fine-tuned dosing harder. Proponents counter that modern NDT manufacturing has tightened consistency considerably since the early 2000s.

The T3 component in NDT introduces a unique consideration. Peak serum T3 levels 2 to 4 hours after an NDT dose may transiently exceed the upper reference range. In younger patients without cardiac disease, this appears to be well tolerated. In patients over 65 or those with existing atrial fibrillation, coronary artery disease, or osteoporosis, the ATA recommends caution with any therapy that raises T3 above the normal range, even transiently 1.

Patient Preference and Quality of Life Data

The Hoang trial's patient preference finding (48.6% preferred NDT vs. 18.6% for levothyroxine) is the most cited piece of evidence favoring Armour Thyroid 2. It is also the most debated. Preference is a subjective endpoint, and the study did not identify which specific symptoms drove the preference. Validated instruments measuring fatigue, depression, and cognitive function showed no significant differences between arms.

One interpretation: the 1.5 kg weight loss on NDT may have influenced satisfaction. Another: higher T3 levels may improve subjective energy or mood in ways that standardized questionnaires fail to capture. A third possibility is expectation bias. Even in a blinded trial, patients who previously heard that "natural" thyroid hormone is superior may report better subjective outcomes, though the double-blind design should have minimized this.

The European Thyroid Association's 2012 position statement on combination T4/T3 therapy reviewed 11 RCTs and found that most showed no difference in quality-of-life measures between T4 monotherapy and combination approaches 5. Only two trials showed a patient preference for the combination arm, and both were among the smaller studies reviewed.

Dr. Antonio Bianco, an endocrinologist at the University of Chicago and a leading researcher on DIO2 polymorphisms, has written: "The fact that 49% of patients preferred desiccated thyroid in a blinded trial is not nothing. We should investigate why, not dismiss it because our instruments could not measure it." This perspective captures the field's tension: the biochemical data show equivalence, but the patient experience data show a signal worth pursuing.

Switching Between the Two: What Clinicians Recommend

The ATA guidelines do not prohibit switching from levothyroxine to NDT, though they recommend against it as a routine practice 1. Most endocrinologists who do prescribe NDT use it as a second-line option for patients who report persistent symptoms (fatigue, weight gain, brain fog, cold intolerance) on levothyroxine despite optimized TSH.

A typical switching protocol starts by converting the current levothyroxine dose to an approximate NDT equivalent. A common conversion: 100 mcg of levothyroxine maps to roughly 1 grain (60 mg) of Armour Thyroid, though some clinicians use 1.5 grains for that dose depending on the patient's clinical response. TSH, free T4, and free T3 should be rechecked at 6 weeks. The T3 component of NDT suppresses TSH more quickly, so clinicians often start at a slightly lower NDT dose than the calculated equivalent and titrate upward.

Switching in the other direction (NDT to levothyroxine) is more straightforward. The total T4 content of the NDT dose is matched, and the exogenous T3 is allowed to wash out over 1 to 2 weeks (T3 half-life is approximately 1 day). TSH may rise transiently during this washout before the levothyroxine reaches steady state at 4 to 6 weeks.

Patients should not switch formulations without physician oversight. Self-adjusting thyroid hormone doses based on symptoms alone risks TSH suppression, which carries real consequences: a TSH below 0.1 mIU/L is associated with a 3.1-fold increased risk of atrial fibrillation over 10 years in adults over 60 7.

Cost and Access Considerations

Generic levothyroxine is one of the most affordable prescription medications available in the United States. GoodRx data show 30-day cash prices ranging from $4 to $15 for most doses. Brand-name Synthroid typically costs $30 to $50 per month without insurance. Nearly all commercial and government insurance plans cover levothyroxine with low copays.

Armour Thyroid is more expensive. A 30-day supply at common doses (1 to 2 grains) runs $30 to $60 cash price, and insurance coverage varies. Some pharmacy benefit managers classify NDT as a non-preferred brand, resulting in higher tier copays. A few insurers require prior authorization or step therapy (documented levothyroxine failure) before covering Armour Thyroid.

NP Thyroid and WP Thyroid are alternative NDT products that may be less expensive than Armour Thyroid in some markets. NP Thyroid was briefly recalled in 2020 by Acella Pharmaceuticals for superpotency issues (certain lots contained up to 115% of the labeled T3 content), which reinforced concerns about NDT manufacturing consistency 8. The recall was resolved, and NP Thyroid returned to the market, but the episode is frequently cited by clinicians who prefer the tighter manufacturing controls of synthetic levothyroxine.

Who Might Benefit from Each Approach

Levothyroxine remains the appropriate first-line choice for the majority of hypothyroid patients: those newly diagnosed, those stable with good symptom control, older adults, patients with cardiac disease, and pregnant women (NDT is not recommended in pregnancy due to T3 variability) 1.

NDT may warrant consideration in a specific clinical scenario: a patient on optimized levothyroxine (TSH 0.5 to 2.5 mIU/L) who continues to report fatigue, weight gain, or cognitive symptoms that cannot be explained by other conditions (depression, sleep apnea, iron deficiency, adrenal insufficiency). The Hoang trial's preference data suggest roughly half of patients may subjectively respond better to NDT, though this signal needs confirmation in larger studies 2.

Patients who should approach NDT with particular caution include those over 65, those with atrial fibrillation or a history of it, patients with osteoporosis or osteopenia, and anyone who has difficulty adhering to split-dose regimens if their clinician recommends dividing the daily NDT dose to smooth T3 peaks.

The bottom line from available evidence: both drugs normalize TSH, neither has proven superior for hard endpoints, and the patient preference signal from the Hoang trial is real but unexplained by validated instruments. Clinicians should discuss the evidence openly, monitor labs closely after any switch, and target a TSH of 0.5 to 2.5 mIU/L regardless of which formulation is chosen.